Tech Company Financing Transactions
Audentes Therapeutics Funding Round
Audentes Therapeutics, based in San Francisco, secured $30 million from OrbiMed, 5AM Ventures and Versant Ventures.
Transaction Overview
Company Name
Announced On
7/19/2013
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series A
Investors
OrbiMed (Lead Investor) (Jonathan Silverstein)
5AM Ventures (Kush Parmar)
Versant Ventures (Thomas Woiwode)
Proceeds Purpose
This funding will allow the Company to further advance its two lead programs, AT001 for X-linked Myotubular Myopathy (XLMTM) and AT002 for Pompe disease, and to evaluate additional candidate programs.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
600 California St. 17th Floor
San Francisco, CA 94108
USA
San Francisco, CA 94108
USA
Phone
Website
Email Address
Overview
Audentes Therapeutics (NASDAQ: BOLD) is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Matthew Patterson
Chief Financial Officer
Thomas Soloway
Chief Operating Officer
Natalie Holles
Vice President
Fulvio Mavilio
VP - Regulatory Affairs
Mary Newman
Browse more venture capital transactions:
Prev: 7/19/2013: mxHero venture capital transaction
Next: 7/19/2013: Lytics venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs